延长半衰期产品在重度甲型血友病且高滴度抑制物患者的免疫耐受诱导中起什么作用？
What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
作者信息
Janbain Maissaa, Pipe Steven
机构信息
Section of Hematology and Medical Oncology, Department of Internal Medicine, Tulane School of Medicine, New Orleans, LA.
Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI.
出版信息
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649. doi: 10.1182/asheducation-2016.1.648.
Abstract
A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.
摘要
一名10岁男孩，有严重甲型血友病病史及高滴度抑制物，使用重组凝血因子VIII（rFVIII）产品和血浆源性FVIII产品进行高剂量免疫耐受诱导（ITI）均失败。他的母亲询问是否应尝试使用半衰期延长的产品进行ITI，特别是考虑使用rFVIIIFc浓缩物。
相似文献
1
What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?延长半衰期产品在重度甲型血友病且高滴度抑制物患者的免疫耐受诱导中起什么作用？
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649. doi: 10.1182/asheducation-2016.1.648.
2
Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.在使用重组因子VIII-Fc融合蛋白进行免疫耐受诱导期间因子VIII抑制物滴度的降低
Pediatr Blood Cancer. 2016 May;63(5):922-4. doi: 10.1002/pbc.25874. Epub 2016 Jan 6.
3
Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.通过大剂量免疫球蛋白诱导免疫耐受，早期根除先天性血友病A患者体内的凝血因子VIII抑制物。
Int J Hematol. 2016 Apr;103(4):473-7. doi: 10.1007/s12185-016-1943-0. Epub 2016 Feb 1.
4
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.重组凝血因子VIII诱导对高反应性抑制物的A型血友病患者的免疫耐受
Haematologica. 2006 Apr;91(4):558-61.
5
The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?免疫耐受诱导（ITI）剂量的争论：国际 ITI 研究是否提供了更清晰的图景？
Haemophilia. 2013 Jan;19 Suppl 1:12-7. doi: 10.1111/hae.12051.
6
Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.在一名来自发展中国家的甲型血友病患者中，低剂量凝血因子 VIII 成功诱导免疫耐受。
Blood Coagul Fibrinolysis. 2016 Sep;27(6):729-31. doi: 10.1097/MBC.0000000000000366.
7
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.在一项观察性免疫耐受诱导研究中，关于高危血友病A抑制物患者使用单一凝血因子VIII/血管性血友病因子浓缩物的免疫耐受的首份前瞻性报告。
Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.
8
The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.使用单一 von Willebrand 因子含血浆源性 FVIII 产品治疗血友病 A 免疫耐受诱导：美国经验。
J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x.
9
Immune tolerance induction in patients with hemophilia A.血友病 A 患者的免疫耐受诱导。
Thromb Res. 2011 Jan;127 Suppl 1:S6-9. doi: 10.1016/j.thromres.2010.10.006. Epub 2010 Nov 5.
10
Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.诱导免疫耐受治疗伴有凝血因子 VIII 抑制物的儿童甲型血友病患者
Haemophilia. 2000 May;6(3):150-7. doi: 10.1046/j.1365-2516.2000.00379.x.
引用本文的文献
1
Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.在具有高抑制剂滴度和免疫耐受诱导治疗成功不良预后因素的阿拉伯裔重度血友病 A 儿童中进行低剂量免疫耐受诱导治疗。
Haemophilia. 2022 Jan;28(1):65-72. doi: 10.1111/hae.14456. Epub 2021 Nov 19.
2
Factor VIII-Fc Activates Natural Killer Cells Fc-Mediated Interactions With CD16.VIII 因子-Fc 激活自然杀伤细胞 Fc 介导的与 CD16 的相互作用。
Front Immunol. 2021 Jun 28;12:692157. doi: 10.3389/fimmu.2021.692157. eCollection 2021.
3
Recombinant factor VIII Fc for the treatment of haemophilia A.Fc 融合的重组凝血因子 VIII 治疗 A 型血友病。
Eur J Haematol. 2021 Jun;106(6):745-761. doi: 10.1111/ejh.13610. Epub 2021 Mar 31.
4
Evolution of Hemophilia Care in India.印度血友病护理的发展历程
Indian J Hematol Blood Transfus. 2019 Oct;35(4):716-721. doi: 10.1007/s12288-018-1059-1. Epub 2018 Dec 19.
5
Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients.延长半衰期凝血因子：血友病患者管理的新时代。
Turk J Haematol. 2019 Aug 2;36(3):141-154. doi: 10.4274/tjh.galenos.2019.2018.0393. Epub 2019 May 15.
本文引用的文献
1
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.重组因子VIII Fc（rFVIIIFc）融合蛋白可降低免疫原性并诱导甲型血友病小鼠产生耐受性。
Cell Immunol. 2016 Mar;301:30-9. doi: 10.1016/j.cellimm.2015.12.008. Epub 2015 Dec 29.
2
Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.在使用重组因子VIII-Fc融合蛋白进行免疫耐受诱导期间因子VIII抑制物滴度的降低
Pediatr Blood Cancer. 2016 May;63(5):922-4. doi: 10.1002/pbc.25874. Epub 2016 Jan 6.
3
Immunogenicity of long-lasting recombinant factor VIII products.长效重组凝血因子VIII产品的免疫原性。
Cell Immunol. 2016 Mar;301:40-8. doi: 10.1016/j.cellimm.2015.12.006. Epub 2015 Dec 19.
4
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.用于预防和治疗重度 A 型血友病儿童出血的重组凝血因子 VIII Fc 融合蛋白。
J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.
5
New predictive approaches for ITI treatment.种植体周感染（ITI）治疗的新预测方法。
Haemophilia. 2014 Sep;20 Suppl 6:27-43. doi: 10.1111/hae.12467.
6
ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.从临床和药物经济学角度看，ITI在血友病抑制物患者优化管理中的选择
Haemophilia. 2014 Sep;20 Suppl 6:17-26. doi: 10.1111/hae.12466.
7
Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review.血管性血友病因子对重型 A 型血友病患者抑制剂清除的影响：系统评价。
Br J Haematol. 2014 Aug;166(4):485-95. doi: 10.1111/bjh.12942. Epub 2014 May 16.
8
Tregitope peptides: the active pharmaceutical ingredient of IVIG?调节性表位肽：静脉注射免疫球蛋白的活性药物成分？
Clin Dev Immunol. 2013;2013:493138. doi: 10.1155/2013/493138. Epub 2013 Dec 25.
9
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.3 期研究重組凝血因子 VIII Fc 融合蛋白在重度 A 型血友病中的作用。
Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13.
10
FcRn: the neonatal Fc receptor comes of age.FcRn：新生儿Fc受体步入成熟阶段。
Nat Rev Immunol. 2007 Sep;7(9):715-25. doi: 10.1038/nri2155. Epub 2007 Aug 17.
Zotero 插件